[Form 3/A] Evaxion A/S Amended Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Evaxion A/S Chief Executive Officer Helen Tayton-Martin filed an amended Form 3 reporting her equity interests in the company. She holds warrants directly over 2,500,000 underlying ordinary shares at an exercise price of $0.1200 per share, expiring on December 31, 2031, vesting monthly over 36 months from the initial exercise date. She also reports indirect ownership of 2,286,150 ordinary shares held by her spouse, James Noble.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider TAYTON-MARTIN HELEN KATRINA

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants — 2,500,000 shares (Direct); Ordinary Shares — 2,286,150 shares (Indirect, By James Noble)

Footnotes (1)

1. Mr. Noble is Dr. Tayton-Martin's spouse. Vesting is 1/36 per month over 36 months from the initial exercise date indicated.

Key Figures

Warrant underlying shares: 2,500,000 shares Warrant exercise price: $0.1200 per share Warrant expiration: December 31, 2031 +2 more

5 metrics

Warrant underlying shares 2,500,000 shares Underlying ordinary shares for CEO warrants, direct holding

Warrant exercise price $0.1200 per share Exercise price for CEO warrants

Warrant expiration December 31, 2031 Expiration date of CEO warrants

Indirect ordinary shares 2,286,150 shares Ordinary shares held indirectly by spouse James Noble

Warrant vesting rate 1/36 per month Monthly vesting over 36 months from initial exercise date

Key Terms

Form 3/A, Warrants, Ordinary Shares, indirect ownership, +1 more

5 terms

Form 3/A regulatory

"filed an amended Form 3 reporting her equity interests"

An amended Form 3 (Form 3/A) is a corrected or updated disclosure filed with regulators that revises an insider’s initial report of their ownership in a public company — typically for officers, directors or large shareholders. Investors use it like a corrected inventory list: it clarifies who owns how many shares and whether earlier reports had errors, helping assess insider confidence, possible conflicts and the accuracy of ownership records that can affect stock valuation and trust.

Warrants financial

"She holds warrants directly over 2,500,000 underlying ordinary shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Ordinary Shares financial

"underlying ordinary shares at an exercise price of $0.1200 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

indirect ownership financial

"She also reports indirect ownership of 2,286,150 ordinary shares"

vesting financial

"Vesting is 1/36 per month over 36 months from the initial exercise date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

TAYTON-MARTIN HELEN KATRINA

(Last) (First) (Middle)

DR. NEERGAARDS VEJ 5F

(Street)

HORSHOLM DK-2970

(City) (State) (Zip)

DENMARK

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evaxion A/S [ EVAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/18/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	2,286,150	I	By James Noble(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	01/11/2025(2)	12/31/2031	Ordinary Shares	2,500,000	$0.12	D

Explanation of Responses:

1. Mr. Noble is Dr. Tayton-Martin's spouse.

2. Vesting is 1/36 per month over 36 months from the initial exercise date indicated.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney. This Form 3/A amends the Form 3 filed on March 18, 2026, which reported Dr. Tayton-Martin's initial holdings using the Issuer's CIK number as an interim measure, pending receipt of access to Dr. Tayton-Martin's filer CIK codes. This Form 3/A has been filed using Dr. Tayton-Martin's CIK codes and reflects her as the Reporting Owner, with no alteration to her beneficial ownership.

	/s/ Michael Baird, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider holdings did EVAX CEO Helen Tayton-Martin report on this Form 3/A?

She reported direct warrants over 2,500,000 underlying ordinary shares at a $0.1200 exercise price, expiring December 31, 2031, plus 2,286,150 ordinary shares held indirectly through her spouse, James Noble, reflecting her combined direct derivative and indirect share interests.

How many Evaxion (EVAX) warrants does the CEO hold and on what terms?

She holds warrants over 2,500,000 underlying ordinary shares with an exercise price of $0.1200 and an expiration date of December 31, 2031. Vesting occurs at 1/36 per month over 36 months from the initial exercise date indicated.

What indirect Evaxion (EVAX) share ownership is disclosed for the CEO?

The filing shows 2,286,150 ordinary shares as indirectly owned by Helen Tayton-Martin through her spouse, James Noble. These are ordinary shares, distinct from the warrants, and are reported as indirect ownership rather than directly held by the CEO.

Does this Evaxion (EVAX) Form 3/A show any insider buying or selling activity?

No specific buying or selling transactions are identified. The entry classifies both records as holdings with unknown transaction codes, indicating the filing primarily updates or clarifies the CEO’s existing direct warrant position and indirect share ownership.

What is the vesting schedule for the Evaxion (EVAX) CEO’s warrants?

The warrants vest at 1/36 per month over 36 months from the initial exercise date indicated. This monthly vesting structure gradually makes additional portions of the 2,500,000 underlying ordinary shares exercisable over the three-year period.